Baxter/Genetics Institute recombinant Factor VIII
Antihemophilic product has been in clinicals since March 1987. It was incorrectly reported in the Oct. 26 edition of "The Pink Sheet" (T&G-4) that the product had not yet entered clinical study.
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.